Longboard Pharmaceuticals, Inc. announced that it will host a conference call to discuss topline data from the PACIFIC Study, a Phase 1b/2a clinical trial evaluating bexicaserin in participants with a broad range of Developmental and Epileptic Encephalopathies.
